# Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

> **NCT06422117** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 408 (estimated)

## Conditions studied

- Central Neuropathic Pain

## Interventions

- **DRUG:** HSK16149 20mg-40mg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06422117
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-08-07
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422117, "Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06422117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*